These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32682839)

  • 1. On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.
    Gopal AD; Wallach JD; Shah SA; Regillo C; Ross JS
    Ophthalmology; 2021 Feb; 128(2):332-334. PubMed ID: 32682839
    [No Abstract]   [Full Text] [Related]  

  • 2. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):557-8. PubMed ID: 23167518
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
    Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
    [No Abstract]   [Full Text] [Related]  

  • 4. The accelerated drug approval.
    Novack GD
    Ocul Surf; 2010 Oct; 8(4):205-7. PubMed ID: 20964983
    [No Abstract]   [Full Text] [Related]  

  • 5. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP
    Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):611. PubMed ID: 23981251
    [No Abstract]   [Full Text] [Related]  

  • 7. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
    Hirota S; Yamaguchi T
    Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 9. Unapproved Ophthalmic Drugs.
    Novack GD
    Ocul Surf; 2016 Apr; 14(2):317-20. PubMed ID: 27107659
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label, not off-limits: the FDA needs to create a safe harbor for off-label drug use.
    Howard P; Copland J
    Mo Med; 2013; 110(2):106-9. PubMed ID: 23724473
    [No Abstract]   [Full Text] [Related]  

  • 11. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):439-440. PubMed ID: 34448621
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of FDA Drug Approval and Labeling.
    Clarridge KE; Chin SJ; Stone KD
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3051-3056. PubMed ID: 36496207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 14. Ethical issues in new drug prescribing.
    Cole LW; Kesselheim JC; Kesselheim AS
    J Bioeth Inq; 2012 Mar; 9(1):77-83. PubMed ID: 23180203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2018 Nov; 34(9):603-604. PubMed ID: 30362869
    [No Abstract]   [Full Text] [Related]  

  • 16. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 17. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):65. PubMed ID: 28099041
    [No Abstract]   [Full Text] [Related]  

  • 18. Notification vs approval.
    Novack GD
    Ocul Surf; 2007 Jul; 5(3):255-8. PubMed ID: 17660899
    [No Abstract]   [Full Text] [Related]  

  • 19. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.